Hopp til innhold

Sigdcellesykdom (pediatri)

Behandling av anemi

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (åpner nytt vindu)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Kilde‎: Lancet Haematol. 2023 ;10(4):e261-71.

Arkiv‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (åpner nytt vindu)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (åpner nytt vindu)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Kilde‎: Acta Haematol 1995;94(3):128-34.

Arkiv‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (åpner nytt vindu)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (åpner nytt vindu)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Kilde‎: Haematologica 2006;91(8):1076-83.

Arkiv‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (åpner nytt vindu)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (åpner nytt vindu)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Kilde‎: J Obstet Gynaecol 2007;27(1):82-3.

Arkiv‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (åpner nytt vindu)